ALK and schwannoma: We confirmed that brigatinib had efficacy comparable to ALK-IN-1 in slowing the growth of schwannoma and meningioma cells lines and also exhibited modest in vitro synergy in growth inhibition of meningioma cells when combined with MK-2206 (Figs 2B–2D and S2).